The molecular link between obesity and diabetes

Current Opinion in Endocrinology and Diabetes

Volumn 3, Issue 1, 1996, Pages 16-23

  Hotamisligil, Gökhan S ^a   Peraldi, Pascal ^a   Spiegelman, Bruce M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002999713     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199602000-00004     Document Type: Article

References (70)

1. Moller DE: Insulin Resistance. U.K., New York: John Wiley & Sons; 1993.
2. Hotamisligil GS, Spiegelman BM: TNFα: a key component of obesity-diabetes link. Diabetes 1994, 43:1271-1276.
3. Olefsky JM, Molina JM: Insulin resistance in man. In Diabetes Mellitus. Edited by Rifkin H, Porte DJ. New York: Elsevier Science Publishing; 1990:121-153.
4. Shepherd PR, Kahn BB: Cellular defects in glucose transport: lessons from animal models and implications for human insulin resistance. In Insulin Resistance. Edited by Moller DE. New York: John Wiley & Sons; 1993:253-300.
5. Katz EB, Stenbit AE, Hatton K, DePinho R, Charron MJ: Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in Glut 4. Nature 1995, 377:151-155. This study demonstrated that animals that do not carry a functional copy of the insulin-sensitive glucose transporter were still able to maintain relatively normal glucose homeostasis. This rather surprising result indicated the presence of compensatory glucose transport systems.
6. Saad MJA, Araki E, Miralpeix M, Rothenberg PL, White MF, Kahn CR: Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J Clin Invest 1992, 90:1839-1849.
7. Thies RS, Molina JM, Ciaraldi TP, Freidenberg GR, Olefsky JM: Insulin-receptor autophosphorylation and endogenous substrate phosphorylation in human adipocytes from control, obese, and NIDDM subjects. Diabetes 1990, 39:250-259.
8. Folli F, Saad MJ, Backer JM, Kahn CR: Insulin stimulation of phosphatidylinositol 3-kinase activity and association with insulin receptor substrate 1 in liver and muscle of the intact rat. J Biol Chem 1992, 267:22171-22177.
9. Heydrick SJ, Jullien D, Gautier N, Tanti J-F, Giorgetti S, Obberghen EV, Le Marchand-Brustel Y: Defect in skeletal muscle phosphatidylinositol-3′-kinase in obese insulin-resistant mice. J Clin Invest 1993, 91:1358-1366.
10. Randle PJ, Garland PB, Hales LN, Newsholme EA: The glucose fatty acid cycle, its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
11. Ferrannini E, Barret EJ, Bevilacqua S, De Fronzo RA: Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983, 72:1737-1747.
12. Svedberg J, Bjorntorp P, Smith U, Lonnroth P: Free-fatty acid inhibition of insulin binding, degradation, and action in isolated rat hepatocytes. Diabetes 1990, 39:570-574.
13. Auberger P, Falquerho L, Contreres JO, Pages G, Le Cam G, Rossi B, Le Cam A: Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitotic activity. Cell 1989, 58:631-640.
14. Sbraccia P, Goodman PA, Maddux BA, Wong KY, Chen Y-DI, Reaven GM, Goldfine ID: Production of inhibitor of insulin receptor tyrosine kinase in fibroblasts from patient with insulin resistance and NIDDM. Diabetes 1991, 40:295-299.
15. Maddux BA, Sbraccia P, Kumakura S, Sasson S, Youngren J, Fisher A, Spencer S, Grupe A, Henzel W, Stewart TA, Raaven GM, Goldfine ID: Membrane glycoproteln PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature 1995, 373:448-451. This interesting study reports the cloning of a natural inhibitor of the insulin receptor tyrosine kinase from fibroblasts of patients with NIDDM.
16. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432. This important work describes the cloning of the ob gene. Mutations in this gene result in severe obesity and diabetes in mice.
17. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P: Recombinant mouse ob protein: evidence for peripheral signal linking adiposity and central neural networks. Science 1995, 269:546-549. This paper describes the metabolic effects of recombinant ob protein on lean and obese mice and demonstrates that this molecule is indeed a critical signal in energy balance. This study demonstrated the effects of ob protein when administered directly into the brain.
18. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269:543-546. This paper describes the metabolic effects of recombinant ob protein on lean and obese mice and demonstrates that this molecule is indeed a critical signal in energy balance.
19. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F: Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995, 269:540-543. This paper describes the metabolic effects of racombinant ob protein on lean and obese mice and demonstrates that this molecule is indeed a critical signal in energy balance. This study also indicated a potential effect of leptin on insulin sensitivity.
20. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
21. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJJR, Hotamisligil GS, Spiegelman BM: Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994, 134:264-270.
22. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM: TNF-α inhibits signaling from insulin receptor. Proc Natl Acad Sci U S A 1994, 91:4854-4858. This paper describes the mechanism by which TNF-α induces insulin resistance in cultured adipocytes and demonstrates the ability of TNF-α to reduce insulin-stimulated tyrosine phosphorylation of the insulin receptor and IRS-1. In addition, this study also demonstrated that in cultured cells other cytokines can interfere with insulin receptor signaling.
23. Hotamisligil GS, Budavari A, Murray DL, Spiegelman BM: Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-α. J Clin Invest 1994, 94:1543-1549. This paper demonstrates that TNF-α is, at least in part, responsible for the reduced tyrosine kinase activity in obesity in whole animals. After neutralization of TNF-α, a significant increase was observed in the signaling capacity of the insulin receptor in obese and insulin resistant fa/fa rats.
24. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Dernyck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV: Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984, 312:724-727.
25. Gray PW, Aggarwal BB, Benton CV, Bringman TS, Henzel WJ, Jarret JA, Leung DW, Moffat BNP, Svedersky LP, Palladino MA, Nedwin GE: Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumor necrosis activity. Nature 1984, 312:721-724.
26. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, Ulevitch R, Cerami A: Identity of tumor necrosis factor and the macrophage secreted factor cachectin. Nature 1985, 316:552-555.
27. Beutler B, Cerami A: The biology of cachectin/TNF-α primary mediator of the host response. Ann Rev Immunol 1989, 7:625-655.
28. Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994, 76:959-962.
29. Vilcek J, Lee TH: Tumor necrosis factor new insights into the molecular mechanisms of its actions. J Biol Chem 1991, 266:7313-7316.
30. Loetscher H, Pan YC, Lahm HW, Gentz R, Brockhaus M, Tabuchi H, Lesslauer W: Molecular cloning and expression of the human 55 kD tumor necrosis factor receptor. Cell 1990, 61:351-359.
31. Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GH, Gatanaga T, Granger GA, Lentz R, Raab H, Kohr WJ, Goeddel DV: Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 1990, 61:361-370.
32. Lewis M, Tartaglia LA, Lee A, Bennet GL, Rice GC, Wong GH, Chen EY, Goeddel DV: Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci U S A 1991, 88:2830-2834.
33. Goodwin RG, Anderson D, Jerzy R, Davis T, Brannan CI, Copeland NG, Jenkins NA, Smith CA: Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor. Mol Cell Biol 1991, 11:3020-3026.
34. Smith CA, Davis T, Anderson D, Solam L, Jerzy R, Dower SK, Cosman D, Goodwin RG: A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990, 248:1019-1023.
35. Tartaglia LA, Goeddel DV: Two TNF receptors. Immunol Today 1992, 13:151-153.
36. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino JMA, Goeddel DV: The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci U S A 1991, 88:9292-9296.
37. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Kronke M, Mak TW: Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993, 73:457-467.
38. Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H: Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993, 364:798-802.
39. Erickson SL, de Sauvage FJ, Carver-Moore K, Pitts-Meek S, Gillett N, Sheehan KCF, Schreiber RD, Goeddel DV, Moore MW: Decreased sensitivity to tumor necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994, 372:560-563. These authors describe the consequences of targeted mutations in both p55 and p75 TNF receptor in mice.
40. Rothe M, Wong SC, Henzel WJ, Goeddel DV: A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994, 78:681-692.
41. Aggarwal BB, Vilcek J: Biological Actions of TNF. In Tumor Necrosis Factors: Structure, Function and Mechanism of Action. Edited by Aggarwal BB, Vilcek J. New York: Marcel Dekker; 1992:239-589.
42. Feingold KR, Grunfeld C: Role of cytokines in inducing hyperlipidemia. Diabetes 1992, 41:97-101.
43. Grunfeld C, Feingold KR: The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 1991, 3:143-158.
44. Lang CH, Dobrescu C, Bagby GJ: Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992, 130:43-52.
45. Torti FM, Dieckmann B, Beutler B, Cerami A, Ringold GM: A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science 1965, 229:867-869.
46. Stephens JM, Pekala PH: Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem 1991, 266:21839-21645.
47. Ohsumi J, Sakakibara S, Yamaguchi J, Miyadai K, Yoshioka S, Fujiwara T, Honkoshi H, Serizawa N: Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology 1994, 135:2279-2282.
48. Szalkowski D, White-Carrington S, Berger J, Zhang B: Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 1995, 136:1474-1481. Indicates a link between the regulation of lipid activated transcription factors and TNF-induced insulin resistance.
49. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Wilson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995, 270:12953-12956.
50. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995, in press.
51. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM: mPPAR gamma 2: tissue specific regulator of an adipocyte enhancer. Genes Dev 1994, 8:1224-1234.
52. Lowel BB, Susulic SV, Hamann A, Lawitts JA, Himms-Hagen J, Boyer BB, Kozak LP, JS F: Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 1993, 366:740-742.
53. Grunfeld C, Feingold KR: Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992, 327:329-337.
54. Copeland GP, Leinster SJ, Davis JC, Hipkin LJ: Insulin resistance in patients with colorectal cancer. Br J Surg 1987, 74:1031-1035.
55. Frayn KN: Effects of bum injury on insulin secretion and on sensitivity to insulin in the rat in vivo. Eur J Clin Invest 1975, 5:331-337.
56. Clowes GHJ, ODonnel TF, Blackburn GL, Maki TN: Energy metabolism and proteolysis in traumatized and septic man. Surg Clin North Am 1976, 56:1169-1184.
57. Marano MA, Moldawer LL, Fong Y, et al.: Cachectin/TNF production in experimental burns and pseudomonas infection. Arch Surg 1988, 123:1383-1386.
58. McCall JL, Tuckey JA, Parry BR: Serum tumor necrosis factor alpha and insulin resistance in gastrointestinal cancer. Br J Surg 1992, 79:1361-1363.
59. Van Der Poll T, Romijn JA, Endert E, Borm JJ, Büller HR, Sauerwein HP: Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol 1991, 261:457-465.
60. White MF, Kahn CR: The insulin signaling system. J Biol Chem 1994, 269:1-4.
61. Bagby GJ, Lang CH, Skrepnik N, Spitzer JJ: Attenuation of glucose metabolic changes resulting from TNF-α administration by adrenergic blockade. Am J Physiol 1992, 262:R628-R635.
62. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A: Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993, 268:26055-26058.
63. Kroder G, Kellerer M, Bossenmaier B, Mühlhöfer A, Haring H-U: TNF-α-induced insulin receptor inhibition depends on phosphatase activation. Diabetes 1995, 44:264A.
64. Hotamisligil GH, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 1995, in press. This study examines in detail the mechanisms of TNF-α-mediated inhibition of insulin receptor signaling and describes the unexpected involvement of IRS-1 in the termination of insulin signaling.
65. Cornelius P, Lee MD, Marlowe M, Pekala PH: Monoklne regulation of glucose transporter mRNA in L6 myotubes. Biochem Biophys Res Comm 1989, 165:429-436.
66. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995, 95:2409-2415. These authors describe the overexpression of TNF-α in adipose tissue of obese humans. They also demonstrate the corrective decreases in adipose TNF-α expression after a weight loss program that results in improved insulin sensitivity.
67. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB: The expression of tumor necrosis factor in adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995, 95:2111-2119. Another paper that demonstrates the correlation between TNF-α expression and the decrease in lipoprotein adipose expression.
68. Norman RA, Bogardus C, Ravussin E: Linkage between obesity and a marker near the tumor necrosis factor-α locus in Pima Indians. J Clin Invest 1995, 96:158-162.
69. Morin CL, Sundquist KO, Eckel RH, Pagliossotti M: A high fat diet elevates adipose tissue-derived tumor necrosis factor-α activity [abstract]. Diabetes 1995, 44:128.
70. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Loefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994, 331:1188-1193. In this work the clinical importance of the treatment of insulin resistance in obesity is demonstrated. Furthermore, the agent used in this study illustrated the fact that thiazolidinedione compounds are effective in the treatment of insulin resistance in humans.